** Shares of Icon ICLR.O fall 8.5% to $199.50 premarket
** Contract research firm sees its 2025 adj EPS between $13 and $15
** The midpoint is lower than Wall Street estimates of $14.83 - LSEG
** The midpoint of co's 2025 rev outlook of $8.05 bln-$8.65 bln is also lower than estimates of $8.50 bln
** "Icon continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers, in both the biotech and large pharma businesses," CEO Steve Cutler says
** "Overall, the guidance reflects a still-hesitant demand environment across both pharma and biotech, which will likely last for an additional 2-4 quarters" - brokerage Evervore ISI
** Co reaffirms 2024 adj EPS and rev outlooks
** ICLR stock fell 25.9% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.